Measurements that Matter – How to Deploy a Connected Ecosystem that Unlocks the Power of Decision Making
December 16th, 2021 | 11 am to 12 pm EST
Register Today to Reserve Your Space!
The explosive growth of patient-centric trials over the last two years has necessitated the pursuit of new, minimally invasive ways to collect high-quality clinical data. This need, when combined with growing evidence around the benefit of personalized treatments has spurned the rapid rise of connected sensors and wearables.
The result? Sponsors and CROs now can collect more data than ever before, derive greater insights from individual participants and trial populations, and can use this information to drive key decision-making for the future of their trials.
However, to unlock this potential, the right mix of processes and technology is needed. Taking data insights, making them actionable, and delivering measurements that matter will be key to bringing effective therapies to patients faster.
It’s with this in mind that we invite you to join our expert panel of clinicians and technology experts as we discuss our expert panel of clinicians and technology experts as we discuss:
- Why the industry has moved towards patient-centric data collection
- What it means for the future of our industry
- How we can deploy sensors and wearables to gain a more holistic view of participants and entire studies
- How to use these views to drive future decision-making
SVP and GM
Connected Sensors and Digital Measures
Gillian (Gill) Livock is SVP & GM, Connected Devices at Medable, responsible for driving collaborations which have united many different stakeholders to focus on bringing effective therapies to patients faster. COVID 19 has demanded even more innovation, collaboration, and resilience as we identify ways to support patients, healthcare professionals and keep clinical trials moving forward by effectively working with our partners.
Gill has over 20 years of experience in life sciences and clinical trials, most recently as Global VP, Corporate Business Development and Partnerships for Definiens AG, part of the Astra Zeneca group. Gill is instrumental in supporting partnerships where digital trial strategies can deliver decentralised solutions and RWE can drive digital therapeutics.
Ariel V. Dowling, PhD
Director of Digital Strategy
Data Sciences Institute at Takeda Pharmaceuticals
Ariel V. Dowling, PhD is a Director of Digital Strategy within the Data Sciences Institute at Takeda Pharmaceuticals. In this role, Ariel oversees the strategy, assessment, and deployment of digital devices and decentralized clinical trials across the organization. She was previously a Senior Clinical Data Scientist at Biogen Inc where she managed the wearable sensors deployed in clinical trials for Parkinson’s Disease. Ariel was the algorithm team lead at MC10 Inc and a senior research scientist at BioSensics LLC. Ariel holds an MS and PhD in Mechanical Engineering from Stanford University and an AB and BE in Mechanical Engineering from Dartmouth College. She currently serves on the Strategic Advisory Board of the Digital Medicine (DiMe) Society.
Associate Director, R & D Digital Health
Tim Ruckh is currently an Associate Director in AstraZeneca’s R&D Digital Health team, a group he has been part of since 2020. He has been with AstraZeneca for three years which also includes time in a role managing central and third-party laboratory sample operations in global clinical trials. Prior to joining AstraZeneca, He spent four years in an R&D role with Verily Life Sciences, dating back to when the group was part of Google[X]. He completed mechanical (B.S, M.S) and biomedical engineering (Ph.D) degrees, and continued on with postdoctoral research at Massachusetts General Hospital and Northeastern University. Tim comes from Wisconsin, but he and his family now call Sweden home.
Digital Medicine Society (DiMe)
Ieuan Clay joined the Digital Medicine (DiMe) society in 2021 as Chief Scientific Officer, where he is responsible for scientific strategy and output. He lectures at ETHZ and FHNW in Digital Health, and is an Editorial Board Member at Karger Digital Biomarkers. Following his PhD at the University of Cambridge which focused on technology and analytics development, he joined Novartis Research in 2010, where he built and led the Digital Endpoints group within Translational Medicine (early clinical portfolio). In 2019, he joined Evidation Health, initially focusing on research strategy and then joining commercial to help build their Heart Health on Achievement health programs in collaboration with the American College of Cardiology.
Cost: No cost!
Schedule conflict? Register and you'll receive a copy of the recording!